Yu Jih-Chang, Hsu Fang-Chi, Chiu Yen-Feng
1Institute of Population Health Sciences, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli, 35053 Taiwan.
2Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Medical City Boulevard, Winston-Salem, NC 27157 USA.
BMC Proc. 2018 Sep 17;12(Suppl 9):48. doi: 10.1186/s12919-018-0132-y. eCollection 2018.
Triglyceride (TG) concentrations decrease in response to fenofibrate treatment, and also are associated with DNA methylation. But how interactions between fenofibrate response and DNA methylation affect TGs remains unclear.
In the present study, we identified and compared differential methylation sites associated with TG concentrations in individuals before and after fenofibrate treatment. We then estimated interactions between fenofibrate treatment and methylation to identify differential methylation effects associated with fenofibrate treatment on TG concentrations using the entire longitudinal family sample. To account for within-family and within-individual corrections, the generalized estimating equations approach was used to estimate main and interaction effects between methylation sites and fenofibrate treatment, adjusting for potential confounders. Analyses were also performed with and without adjusting for high-density lipoprotein (HDL) concentrations.
Prior to fenofibrate treatment, 23 cytosine-phosphate-guanine (CpG) sites were significantly associated with TG concentrations, while only 13 CpG sites were identified posttreatment, adjusting for HDL. Without adjusting for HDL, pretreatment, 20 CpG sites were significantly associated with TG concentrations, while only 12 CpG sites were identified posttreatment. Among these sites, only one differential site (cg19003390 in the gene) overlapped from pre- and posttreatment measurements regardless of HDL adjustment. Furthermore, 11 methylation sites showed substantial interaction effects ( < 1.43 × 10with Bonferroni correction) with or without HDL adjustment when using the whole longitudinal data.
Our analyses suggest that DNA methylation likely modified the effect of fenofibrate on TG concentrations. Differential fenofibrate-associated methylation sites on TGs differed with and without adjusting for HDL concentrations, suggesting that these HDLs and TGs might share some common epigenetic processes.
非诺贝特治疗后甘油三酯(TG)浓度降低,且与DNA甲基化有关。但非诺贝特反应与DNA甲基化之间的相互作用如何影响TG仍不清楚。
在本研究中,我们鉴定并比较了非诺贝特治疗前后个体中与TG浓度相关的差异甲基化位点。然后,我们估计非诺贝特治疗与甲基化之间的相互作用,以使用整个纵向家庭样本确定与非诺贝特治疗相关的对TG浓度的差异甲基化效应。为了考虑家庭内部和个体内部的校正,使用广义估计方程方法来估计甲基化位点与非诺贝特治疗之间的主要和相互作用效应,并对潜在的混杂因素进行调整。在调整和不调整高密度脂蛋白(HDL)浓度的情况下也进行了分析。
在非诺贝特治疗前,23个胞嘧啶-磷酸-鸟嘌呤(CpG)位点与TG浓度显著相关,而在调整HDL后,治疗后仅鉴定出13个CpG位点。在不调整HDL的情况下,治疗前20个CpG位点与TG浓度显著相关,而治疗后仅鉴定出12个CpG位点。在这些位点中,无论是否调整HDL,治疗前后测量中只有一个差异位点(基因中的cg19003390)重叠。此外,当使用整个纵向数据时,无论是否调整HDL,11个甲基化位点都显示出显著的相互作用效应(经Bonferroni校正后P<1.43×10)。
我们的分析表明,DNA甲基化可能改变了非诺贝特对TG浓度的影响。与TG相关的非诺贝特差异甲基化位点在调整和不调整HDL浓度时有所不同,表明这些HDL和TG可能共享一些共同的表观遗传过程。